[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1122052T1 - Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] toy hiv - Google Patents

Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] toy hiv

Info

Publication number
CY1122052T1
CY1122052T1 CY20191100891T CY191100891T CY1122052T1 CY 1122052 T1 CY1122052 T1 CY 1122052T1 CY 20191100891 T CY20191100891 T CY 20191100891T CY 191100891 T CY191100891 T CY 191100891T CY 1122052 T1 CY1122052 T1 CY 1122052T1
Authority
CY
Cyprus
Prior art keywords
inhibitory activity
integration
hiv integrase
polycyclic carbamoylpyridone
carbamoylpyridone derivative
Prior art date
Application number
CY20191100891T
Other languages
English (en)
Inventor
Brian Alvin Johns
Takashi Kawasuji
Teruhiko Taishi
Yoshiyuki Taoda
Original Assignee
Viiv Healthcare Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122052(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Company filed Critical Viiv Healthcare Company
Publication of CY1122052T1 publication Critical patent/CY1122052T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση πρόκειται να παράσχει μια καινοφανή ένωση που φαίνεται πιο κάτω, που έχει την δραστηριότητα κατά του ιού, ειδικότερα δε την ανασταλτική δραστηριότητα της ιντεγκράσης του Ηiv, και φάρμακο που περιέχει την ίδια, ειδικότερα φάρμακο κατά του Ηiv.
CY20191100891T 2005-04-28 2019-08-20 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] toy hiv CY1122052T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2005131161 2005-04-28
JP2005312076 2005-10-27
EP06758843.4A EP1874117B8 (en) 2005-04-28 2006-04-28 Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
EP12159079.8A EP2527007B1 (en) 2005-04-28 2006-04-28 Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
EP16154531.4A EP3045206B2 (en) 2005-04-28 2006-04-28 Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
PCT/US2006/016604 WO2006116764A1 (en) 2005-04-28 2006-04-28 Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Publications (1)

Publication Number Publication Date
CY1122052T1 true CY1122052T1 (el) 2020-10-14

Family

ID=37215098

Family Applications (7)

Application Number Title Priority Date Filing Date
CY20131101061T CY1115151T1 (el) 2005-04-28 2013-11-27 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] του hiv
CY20141100201T CY1116331T1 (el) 2005-04-28 2014-03-13 Παραγωγο πολυκυκλικης καρβαμοϋλοπυριδονης με ανασταλτικη ενεργοτητα της ιντεγκρασης του ηiv
CY2014024C CY2014024I2 (el) 2005-04-28 2014-06-25 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)κρασης [ενσωματασης] του hiv
CY20181100633T CY1120345T1 (el) 2005-04-28 2018-06-19 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης[ενσωματασης] toy hiv
CY20191100891T CY1122052T1 (el) 2005-04-28 2019-08-20 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] toy hiv
CY2021016C CY2021016I2 (el) 2005-04-28 2021-05-26 Παραγωγο πολυκυκλικης καρβαμοϋλοπυριδονης με ανασταλτικη ενεργοτητα της ιντεγκρασης του ηiv
CY20211100866T CY1124601T1 (el) 2005-04-28 2021-10-06 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] toy hiv

Family Applications Before (4)

Application Number Title Priority Date Filing Date
CY20131101061T CY1115151T1 (el) 2005-04-28 2013-11-27 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] του hiv
CY20141100201T CY1116331T1 (el) 2005-04-28 2014-03-13 Παραγωγο πολυκυκλικης καρβαμοϋλοπυριδονης με ανασταλτικη ενεργοτητα της ιντεγκρασης του ηiv
CY2014024C CY2014024I2 (el) 2005-04-28 2014-06-25 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)κρασης [ενσωματασης] του hiv
CY20181100633T CY1120345T1 (el) 2005-04-28 2018-06-19 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης[ενσωματασης] toy hiv

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY2021016C CY2021016I2 (el) 2005-04-28 2021-05-26 Παραγωγο πολυκυκλικης καρβαμοϋλοπυριδονης με ανασταλτικη ενεργοτητα της ιντεγκρασης του ηiv
CY20211100866T CY1124601T1 (el) 2005-04-28 2021-10-06 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] toy hiv

Country Status (29)

Country Link
US (22) US8129385B2 (el)
EP (9) EP3284519A1 (el)
JP (2) JP4295353B2 (el)
KR (4) KR101580310B1 (el)
AU (1) AU2006239177B8 (el)
BR (1) BRPI0610030B8 (el)
CA (1) CA2606282C (el)
CY (7) CY1115151T1 (el)
DK (6) DK3372281T3 (el)
EA (1) EA014162B1 (el)
ES (7) ES2446324T3 (el)
FI (1) FIC20210017I1 (el)
FR (1) FR14C0041I2 (el)
HK (4) HK1107227A1 (el)
HU (6) HUE044978T2 (el)
IL (4) IL186555A (el)
LT (4) LT3045206T (el)
LU (2) LU92446I2 (el)
MA (1) MA29460B1 (el)
MX (2) MX302718B (el)
NL (2) NL300676I2 (el)
NO (5) NO339525B1 (el)
NZ (1) NZ562339A (el)
PL (5) PL3372281T3 (el)
PT (5) PT3284520T (el)
SI (6) SI3045206T1 (el)
TW (1) TWI378931B (el)
VN (1) VN34404A1 (el)
WO (1) WO2006116764A1 (el)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2360222T3 (es) 2003-12-24 2011-06-02 Biota Scientific Management Pty. Ltd. Agentes policíclicos para el tratamiento de infecciones respiratorias por virus sincicial.
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
SI3045206T1 (en) 2005-04-28 2018-07-31 Viiv Healthcare Company A polycyclic carbamoylpyridone derivative with inhibitory activity for the HIV integrase
US7741315B2 (en) 2005-05-10 2010-06-22 Merck Sharp & Dohme Corp. HIV integrase inhibitors
ATE517899T1 (de) 2005-10-04 2011-08-15 Angeletti P Ist Richerche Bio Hiv-integrasehemmer
JP5131689B2 (ja) * 2005-10-27 2013-01-30 塩野義製薬株式会社 Hivインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
TWI423972B (zh) 2006-09-28 2014-01-21 Biota Scient Management 治療呼吸系融合細胞病毒感染之多環劑
JP5269086B2 (ja) 2007-11-15 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスの複製阻害薬
WO2009062288A1 (en) 2007-11-15 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EA201200631A1 (ru) 2007-11-16 2012-11-30 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
PT2320908E (pt) 2008-07-25 2014-03-06 Shionogi & Co Pró-fármacos de dolutegravir
ES2395705T3 (es) * 2008-07-25 2013-02-14 Glaxosmithkline Llc Compuestos químicos
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
KR101700267B1 (ko) * 2008-07-25 2017-01-26 비이브 헬쓰케어 컴퍼니 화합물
AU2014277831C1 (en) * 2008-12-11 2022-10-06 Shionogi & Co. Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
JP5572168B2 (ja) * 2008-12-11 2014-08-13 ビーブ・ヘルスケア・カンパニー カルバモイルピリドンhivインテグラーゼ阻害剤の製造方法および中間体
KR101663222B1 (ko) * 2008-12-11 2016-10-06 시오노기세야쿠 가부시키가이샤 말톨 에테르 방법 및 중간체
BRPI0923217A2 (pt) 2008-12-11 2017-05-23 Glaxosmithkline Llc processos para a preparação de um composto de piridona, e para a preparação de uma forma cristalina, composto, sal ou um hidrato deste, forma cristalina de um sal de sódio ou um hidrato deste, e, composição farmacêutica.
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
ES2671550T3 (es) 2009-06-15 2018-06-07 Shionogi & Co., Ltd. Derivado de carbamoilpiridona policíclica sustituida
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
CA2777664C (en) 2009-10-13 2014-06-10 Johannes Wilhelmus J. Thuring Macrocyclic integrase inhibitors
AU2014202406C1 (en) * 2010-01-27 2019-03-07 Viiv Healthcare Company Antiviral therapy
AU2014202404C1 (en) * 2010-01-27 2022-06-23 Viiv Healthcare Company Antiviral therapy
MA34002B1 (fr) * 2010-01-27 2013-02-01 Glaxosmithkline Llc Thérapie antivirale
TWI508968B (zh) 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
SG183484A1 (en) * 2010-02-26 2012-09-27 Japan Tobacco Inc 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
TWI582097B (zh) 2010-03-23 2017-05-11 Viiv醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
RU2567385C2 (ru) 2010-04-02 2015-11-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Макроциклические ингибиторы интегразы
US9216995B2 (en) 2010-04-12 2015-12-22 Shionogi & Co., Ltd. Pyridone derivative having integrase inhibitory activity
WO2012006104A2 (en) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
PT3456721T (pt) * 2010-08-05 2021-05-04 Shionogi & Co Método de produção de compostos possuindo atividade inibitória de integrase de vih
TWI577377B (zh) * 2010-09-16 2017-04-11 Viiv醫療保健公司 醫藥組合物
WO2012039414A1 (ja) 2010-09-24 2012-03-29 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体のプロドラッグ
US8796303B2 (en) 2010-11-26 2014-08-05 Biota Scientific Management Pty Ltd. Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
US20140213553A1 (en) * 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
ES2613180T3 (es) 2011-09-14 2017-05-23 Mapi Pharma Limited Forma amorfa de la sal sódica dolutegravir
BR112014008896A2 (pt) * 2011-10-12 2017-04-18 Shionogi & Co derivado de piridona policíclico tendo atividade inibidora de integrase
PE20142454A1 (es) 2011-12-28 2015-02-07 Global Blood Therapeutics Inc Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
PT3608325T (pt) * 2012-12-21 2022-10-17 Gilead Sciences Inc Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica
SG11201504982PA (en) * 2012-12-27 2015-07-30 Japan Tobacco Inc SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
CA2897137A1 (en) 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
EP2767272A1 (en) 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
WO2014128545A2 (en) 2013-02-19 2014-08-28 Aurobindo Pharma Limited An improved process for the preparation of dolutegravir
MY183637A (en) 2013-03-15 2021-03-04 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EA034922B1 (ru) 2013-03-15 2020-04-07 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG11201507453VA (en) 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014172188A2 (en) 2013-04-16 2014-10-23 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
EP3008044B1 (en) * 2013-06-13 2018-11-21 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2015001572A2 (en) * 2013-07-04 2015-01-08 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
PT3019503T (pt) 2013-07-12 2017-11-27 Gilead Sciences Inc Compostos carbamoílpiridona- policíclicos e seu uso para o tratamento de infecções por hiv
NO2865735T3 (el) 2013-07-12 2018-07-21
WO2015009927A1 (en) 2013-07-17 2015-01-22 Ratiopharm Gmbh Dolutegravir salts
WO2015019310A1 (en) 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof
WO2015039348A1 (en) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
TN2016000090A1 (en) 2013-09-27 2017-07-05 Merck Sharp & Dohme Substituted quinolizine derivatives useful as hiv integrase inhibitors.
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015092752A1 (en) 2013-12-20 2015-06-25 Mylan Laboratories Ltd. Novel crystalline form of dolutegravir sodium
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
EP3096763B1 (en) * 2014-01-21 2019-12-25 Laurus Labs Limited Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
CN114181195A (zh) 2014-02-07 2022-03-15 全球血液疗法股份有限公司 一种化合物的结晶多晶型物
WO2015138933A1 (en) 2014-03-13 2015-09-17 Assia Chemical Industries Ltd. Solid state forms of dolutegravir sodium
CN106866702B (zh) * 2014-03-19 2019-03-19 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
WO2015140569A1 (en) 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
ZA201503540B (en) * 2014-05-20 2016-10-26 Cipla Ltd Process for preparing polycyclic carbamoyl pyridone derivatives
TW201613936A (en) * 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) * 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (el) * 2014-06-20 2018-06-23
JPWO2016027879A1 (ja) * 2014-08-22 2017-06-01 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
EP3203995A4 (en) 2014-10-09 2019-05-15 Board of Regents of the University of Nebraska COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3045461A1 (en) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
CN107531614B (zh) 2015-02-06 2020-04-10 迈兰实验室有限公司 德罗格韦的制备方法
CZ201599A3 (cs) 2015-02-13 2016-08-24 Zentiva, K.S. Pevné formy solí dolutegraviru a způsob jejich přípravy
WO2016154527A1 (en) * 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
PT3466490T (pt) 2015-04-02 2020-12-24 Gilead Sciences Inc Compostos de carbamoilpiridona policíclicos e sua utilização farmacêutica
NZ736259A (en) * 2015-04-28 2019-09-27 Shionogi & Co Substituted polycyclic pyridone derivative and prodrugs thereof
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
CZ2015537A3 (cs) 2015-08-04 2017-02-15 Zentiva, K.S. Pevné formy amorfního dolutegraviru
US10597404B2 (en) 2015-08-19 2020-03-24 Laurus Labs Ltd. Polymorphs of dolutegravir and salts thereof
CN108348473B (zh) 2015-11-09 2021-06-18 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
EP3377066B1 (en) 2015-11-17 2021-04-07 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
TW201731509A (zh) 2015-12-04 2017-09-16 全球血液治療公司 針對2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之劑量方案
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017109649A1 (en) 2015-12-21 2017-06-29 Lupin Limited Process for the preparation of hiv integrase inhibitors
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
US11117904B2 (en) 2016-06-23 2021-09-14 Viiv Healthcare Company Compositions and methods for the delivery of therapeutics
EP3496718A4 (en) 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
WO2018029565A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited A multi-class anti-retroviral composition
CN109789144B (zh) * 2016-08-12 2022-04-15 马德拉医疗公司 蛋白激酶调节剂
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
EP3515438B1 (en) * 2016-09-21 2022-03-02 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
AU2017367714B2 (en) 2016-12-02 2020-11-12 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as HIV integrase inhibitors
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
EP3573984A4 (en) 2017-01-26 2020-07-29 Merck Sharp & Dohme Corp. USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS
EP3363802B1 (en) 2017-02-16 2019-11-20 Sandoz AG Crystalline form of cabotegravir sodium
AU2018221379B2 (en) 2017-02-16 2021-11-04 ViiV Healthcare UK (No.3) Limited Crystalline forms of cabotegravir sodium
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
KR20200031658A (ko) 2017-07-21 2020-03-24 비이브 헬쓰케어 컴퍼니 Hib 감염 및 aids를 치료하기 위한 요법
WO2019048808A1 (en) 2017-09-07 2019-03-14 Cipla Limited NOVEL POLYMORPHS OF DOLUTÉGRAVIR SODIQUE
US11286262B2 (en) 2017-10-06 2022-03-29 Shionogi & Co., Ltd. Stereoselective process for preparing substituted polycyclic pyridone derivatives
CA3126348A1 (en) 2018-01-12 2020-07-18 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2019159199A1 (en) 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
CA3132832A1 (en) 2018-04-09 2019-10-17 Howard E. Gendelman Antiviral prodrugs and formulations thereof
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
CN112513042B (zh) 2018-05-31 2023-09-29 盐野义制药株式会社 多环氨基甲酰基吡啶酮衍生物
SG11202011386QA (en) 2018-05-31 2020-12-30 Shionogi & Co Polycyclic pyridone derivative
TWI820141B (zh) * 2018-05-31 2023-11-01 日商鹽野義製藥股份有限公司 衍生物
WO2020012408A2 (en) 2018-07-12 2020-01-16 Laurus Labs Limited A process for purification of protected polycyclic carbamoylpyridone derivatives
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
EP4234561A3 (en) 2018-10-22 2023-09-13 Board of Regents of the University of Nebraska Antiviral prodrugs and nanoformulations thereof
ES2927041T3 (es) 2019-03-22 2022-11-03 Gilead Sciences Inc Compuestos de carbamoilpiridona tricíclicos con puente y su uso farmacéutico
RU2717101C1 (ru) * 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
WO2021107066A1 (ja) 2019-11-28 2021-06-03 塩野義製薬株式会社 インテグラーゼ阻害剤及び抗hiv薬を組み合わせることを特徴とするhiv感染症の予防及び治療用医薬
IL293566A (en) 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
BR112022015771A2 (pt) * 2020-02-24 2022-10-11 Gilead Sciences Inc Compostos tetracíclicos para tratar a infecção por hiv
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
JP2023539344A (ja) 2020-09-01 2023-09-13 ヴィーブ、ヘルスケア、カンパニー カボテグラビルおよびレボノルゲストレルの組合せ
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
JP2024500322A (ja) 2020-12-07 2024-01-09 ヴィーブ、ヘルスケア、カンパニー 併用療法
TWI824384B (zh) 2021-01-19 2023-12-01 美商基利科學股份有限公司 經取代之吡啶并三𠯤化合物及其用途
WO2022253294A1 (zh) 2021-06-03 2022-12-08 江苏恒瑞医药股份有限公司 具有整合酶抑制活性的吡啶酮化合物及其药用用途
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
WO2023102374A1 (en) 2021-12-03 2023-06-08 Viiv Healthcase Company Process of synthesizing (r)-3-aminobutan-1-ol
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240270756A1 (en) * 2023-01-18 2024-08-15 Ascletis Bioscience Co., Ltd. Integrase Inhibitor and Use Thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959316A (en) * 1972-03-13 1976-05-25 Snam Progetti S.P.A. Procedure for propylene oxide synthesis
JPH0296506A (ja) 1988-09-30 1990-04-09 Daicel Chem Ind Ltd 除草剤組成物
JP2533796B2 (ja) * 1988-10-18 1996-09-11 ダイセル化学工業株式会社 5−アルコキシピリジン−3−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2551472B2 (ja) 1988-10-18 1996-11-06 ダイセル化学工業株式会社 5−アルコキシ−γ−ピロン−3−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
US6093732A (en) 1997-12-22 2000-07-25 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
WO2001095905A1 (en) 2000-06-14 2001-12-20 Shionogi & Co., Ltd. Inhibitor for enzyme having two divalent metal ions as active centers
US6580562B2 (en) 2000-07-24 2003-06-17 Yazaki Corporation On-vehicle display unit
US6384263B1 (en) 2000-08-04 2002-05-07 E. I. Du Pont De Nemours And Company Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
ATE364385T1 (de) 2000-10-12 2007-07-15 Merck & Co Inc Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
JP2003032772A (ja) 2001-07-12 2003-01-31 Foster Electric Co Ltd 耳掛け式イヤホン
BR0211750A (pt) 2001-08-10 2004-10-13 Shionogi & Co Agente antiviral
US7232819B2 (en) 2001-10-26 2007-06-19 Istituto Di Ricerche Di Biologia P. Angeletti S.P.A. Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
CN102219750B (zh) 2001-10-26 2013-05-29 P.安杰莱蒂分子生物学研究所 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂
CA2472372C (en) 2002-01-17 2010-08-17 Melissa Egbertson Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
US7109186B2 (en) 2002-07-09 2006-09-19 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2004024693A1 (ja) 2002-08-13 2004-03-25 Shionogi & Co., Ltd. Hivインテグラーゼ阻害活性を有するヘテロ環化合物
CA2498111A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
NZ540729A (en) 2002-12-27 2008-03-28 Angeletti P Ist Richerche Bio Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds useful as HIV integrase inhibitors
US6960680B2 (en) 2003-01-08 2005-11-01 Rhodia Chirex, Inc. Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
WO2004101512A2 (en) 2003-05-13 2004-11-25 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
AU2003273190A1 (en) * 2003-08-12 2005-02-25 Rachel Beijer Scheduled message service
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4530642B2 (ja) 2003-10-31 2010-08-25 オリンパス株式会社 内視鏡装置
KR20070002006A (ko) 2004-02-11 2007-01-04 스미스클라인 비참 코포레이션 Hiv 인테그라제 억제제
AU2005221864A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa HIV integrase inhibitors
CN1929737A (zh) 2004-03-09 2007-03-14 默克公司 Hiv整合酶抑制剂
CN1964975B (zh) 2004-05-07 2011-11-30 默沙东公司 Hiv整合酶抑制剂
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
ATE516026T1 (de) 2005-02-21 2011-07-15 Shionogi & Co Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung
US7981879B2 (en) 2005-03-31 2011-07-19 Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. HIV integrase inhibitors
SI3045206T1 (en) * 2005-04-28 2018-07-31 Viiv Healthcare Company A polycyclic carbamoylpyridone derivative with inhibitory activity for the HIV integrase
JP2005312076A (ja) 2005-05-26 2005-11-04 Olympus Corp 電子撮像装置
EP1910363A4 (en) 2005-08-04 2010-05-26 Glaxosmithkline Llc INHIBITORS OF HIV INTEGRASE
JP5131689B2 (ja) 2005-10-27 2013-01-30 塩野義製薬株式会社 Hivインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体

Also Published As

Publication number Publication date
US8410103B2 (en) 2013-04-02
KR20160003889A (ko) 2016-01-11
US9273065B2 (en) 2016-03-01
PT3284520T (pt) 2019-09-10
PL3372281T3 (pl) 2021-12-27
EP2527007B1 (en) 2016-03-30
SI1874117T1 (sl) 2014-01-31
EA014162B1 (ru) 2010-10-29
ES2743531T3 (es) 2020-02-19
CY2021016I2 (el) 2021-12-31
KR20140097438A (ko) 2014-08-06
US20190284208A1 (en) 2019-09-19
US20130172559A1 (en) 2013-07-04
LTC2465580I2 (el) 2022-10-10
US20170267693A1 (en) 2017-09-21
IL225207A (en) 2017-11-30
EP1874117A4 (en) 2009-12-30
HK1172282A1 (en) 2013-04-19
HUS1400039I1 (hu) 2016-08-29
CY1120345T1 (el) 2019-07-10
JP2009079058A (ja) 2009-04-16
EP3045206A1 (en) 2016-07-20
CY2014024I1 (el) 2015-12-09
DK3372281T3 (da) 2021-09-27
NL301109I1 (nl) 2021-09-15
NO20161315A1 (no) 2007-11-22
PL2465580T3 (pl) 2014-05-30
FR14C0041I2 (fr) 2015-11-13
ES2446324T3 (es) 2014-03-07
ES2437268T3 (es) 2014-01-09
ES2667868T5 (es) 2023-06-01
US20160304535A1 (en) 2016-10-20
EA200702080A1 (ru) 2008-04-28
US11267823B2 (en) 2022-03-08
EP3187226A1 (en) 2017-07-05
NO2021018I1 (no) 2021-05-10
EP2465580A1 (en) 2012-06-20
PT1874117E (pt) 2013-10-17
US20170260203A1 (en) 2017-09-14
EP3284520B1 (en) 2019-06-05
IL186555A0 (en) 2008-01-20
CY1116331T1 (el) 2017-02-08
EP2527007A1 (en) 2012-11-28
NL301109I2 (nl) 2021-09-15
PT2465580E (pt) 2014-02-25
KR20080009733A (ko) 2008-01-29
AU2006239177B8 (en) 2012-02-16
CY1115151T1 (el) 2015-12-09
EP1874117A1 (en) 2008-01-09
BRPI0610030B1 (pt) 2020-09-15
NO339525B1 (no) 2016-12-27
KR101504998B1 (ko) 2015-03-23
ES2567197T3 (es) 2016-04-20
US8778943B2 (en) 2014-07-15
JP2008540343A (ja) 2008-11-20
US20190152990A1 (en) 2019-05-23
DK3187225T3 (da) 2022-02-28
EP3045206B2 (en) 2023-02-15
DK2465580T3 (en) 2014-03-10
LT3372281T (lt) 2021-12-10
HK1249742A1 (zh) 2018-11-09
CY2014024I2 (el) 2015-12-09
US20200339598A1 (en) 2020-10-29
SI2465580T1 (sl) 2014-04-30
SI3187225T1 (sl) 2022-04-29
US20170145033A1 (en) 2017-05-25
FR14C0041I1 (el) 2014-06-27
VN34404A1 (en) 2013-07-25
US20150232479A1 (en) 2015-08-20
IL215788A0 (en) 2011-12-29
NO2017010I1 (no) 2017-03-27
NO340111B1 (no) 2017-03-13
EP3187225B1 (en) 2022-01-05
IL186555A (en) 2016-10-31
HUE037795T2 (hu) 2018-09-28
US20160207939A1 (en) 2016-07-21
LU92446I2 (fr) 2015-10-29
NZ562339A (en) 2011-01-28
EP3284519A8 (en) 2018-04-18
EP3284520A1 (en) 2018-02-21
EP1874117B1 (en) 2013-08-28
DK1874117T3 (da) 2013-09-23
DK3284520T3 (da) 2019-09-16
ES2892304T3 (es) 2022-02-03
US20240279238A1 (en) 2024-08-22
EP3284519A1 (en) 2018-02-21
US8129385B2 (en) 2012-03-06
CY2021016I1 (el) 2021-10-15
NO2017010I2 (no) 2017-03-27
TW200716635A (en) 2007-05-01
KR20130133061A (ko) 2013-12-05
US20140200209A1 (en) 2014-07-17
NL300676I2 (el) 2016-10-11
DK3045206T3 (en) 2018-05-22
HK1107227A1 (en) 2008-04-03
US20120115875A1 (en) 2012-05-10
US20090318421A1 (en) 2009-12-24
AU2006239177A1 (en) 2006-11-02
EP3187225A1 (en) 2017-07-05
LTPA2021512I1 (el) 2021-07-12
AU2006239177B2 (en) 2011-10-20
EP1874117B8 (en) 2014-03-12
US20170224694A1 (en) 2017-08-10
PL1874117T3 (pl) 2014-01-31
NO2023042I1 (no) 2023-11-08
PL3284520T3 (pl) 2020-01-31
SI3045206T1 (en) 2018-07-31
KR101848819B1 (ko) 2018-04-16
EP3045206B1 (en) 2018-03-28
US20170209454A1 (en) 2017-07-27
MX2007013351A (es) 2008-01-21
CY1124601T1 (el) 2022-07-22
LT3284520T (lt) 2019-09-25
PT3372281T (pt) 2021-10-14
BRPI0610030A2 (pt) 2011-10-11
LT3045206T (lt) 2018-06-11
HUE056603T2 (hu) 2022-02-28
KR101580310B1 (ko) 2016-01-04
EP3372281A1 (en) 2018-09-12
CA2606282A1 (en) 2006-11-02
SI3284520T1 (sl) 2019-10-30
PL3045206T3 (pl) 2018-08-31
TWI378931B (en) 2012-12-11
US20170253616A1 (en) 2017-09-07
MX302718B (es) 2012-08-27
BRPI0610030B8 (pt) 2022-01-11
FIC20210017I1 (fi) 2021-06-10
ES2906792T3 (es) 2022-04-20
NO20075165L (no) 2007-11-22
JP4295353B2 (ja) 2009-07-15
PT3045206T (pt) 2018-07-05
HUS2100022I1 (hu) 2021-07-28
US20220213121A1 (en) 2022-07-07
CA2606282C (en) 2016-04-26
HUS2100023I1 (hu) 2021-07-28
MX312216B (en) 2013-08-12
HK1251191A1 (zh) 2019-01-25
WO2006116764A1 (en) 2006-11-02
ES2667868T3 (es) 2018-05-14
US20170224695A1 (en) 2017-08-10
EP2465580B1 (en) 2013-12-18
IL225206A (en) 2017-11-30
US9051337B2 (en) 2015-06-09
HUE044978T2 (hu) 2019-11-28
MA29460B1 (fr) 2008-05-02
US10927129B2 (en) 2021-02-23
US20170369509A1 (en) 2017-12-28
EP3372281B1 (en) 2021-07-07
KR101363875B1 (ko) 2014-02-21
US20160137666A1 (en) 2016-05-19
US20170029438A1 (en) 2017-02-02
SI3372281T1 (sl) 2021-11-30
LUC00210I2 (el) 2022-10-07

Similar Documents

Publication Publication Date Title
CY1122052T1 (el) Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] toy hiv
EA200801144A1 (ru) Полициклическое карбамоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич
NL300933I2 (nl) Letermovir
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
NO20034660D0 (no) Spiropyrazolforbindelser
WO2004035569A3 (de) Neue verbindungen mit antibakterieller aktivität
PT1453512E (pt) Derivados de acetileno tendo actividade antagonistica do mglur 5
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
DE60205870D1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
NO20065836L (no) Linezolidkrystallform
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
CR9234A (es) Derivados de 2,4(4,6) pirimidina
PT1379520E (pt) Antagonistas (nao-aril)-heterociclicos n-substituidos de nmda/nr2b
EP2075011A3 (en) Prodrugs containing bio-cleavable disulfide linkers
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
WO2001082909A3 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
WO2005007103A3 (en) Use of parthenolide derivatives as antileukemic and cytotoxic agents
MXPA03009602A (es) Analogos de nociceptina.
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
WO2002024697A1 (fr) Composes spiro et inhibiteurs de molecules d'adhesion contenant ces composes comme ingredient actif
CY1108916T1 (el) Υποκαθιστουμενες πυρρολες, οι ενωσεις που τις περιεχουν, διαδικασια παρασκευης και χρηση τους
WO2007017518A3 (en) Pesticidal mixtures comprising a phenylsemicarbazone
BR0115139A (pt) Compostos bis-heterocìclicos com atividade antitumor e quimiossensibilizante
AU2003281468A1 (en) P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient